Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics

Clinical Cancer Research

Volumn 17, Issue 21, 2011, Pages 6634-6640

  Scher, Howard I ^a   Nasso, Shelley Fuld ^b   Rubin, Eric H ^c   Simon, Richard ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Susan G Komen for the Cure   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ALPHARADIN; ANDROGEN RECEPTOR; BIOLOGICAL MARKER; CABAZITAXEL; MVD 3100; PROVENGE; RADIOISOTOPE; RADIUM 223 CHLORIDE; UNCLASSIFIED DRUG;

ADAPTIVE CLINICAL TRIAL DESIGN; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; DRUG APPROVAL; DRUG DESIGN; DRUG RESEARCH; HEALTH CARE COST; HUMAN; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STUDY DESIGN; SYSTEMATIC ERROR;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80455173464     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1105     Document Type: Review

References (30)

1. Roberts SA, Karnes EK, Allen JD, Benner JS, Sigal EV, McClellan M. Achieving the goals of effective, safe, and individualized cancer care. Clin Cancer Res 2011;17:6632-3.
2. Turteltaub KW, Davis MA, Burns-Naas LA, Lawton MP, Clark AM, Reynolds JA. Identification and elucidation of the biology of adverse events: the challenges of safety assessment and translational medicine. Clin Cancer Res 2011;17: 6641-5.
3. Cleeland CS, O'Mara A, Zagari M, Baas C. Integrating pain metrics into oncology clinical trials. Clin Cancer Res 2011;17:6646-50.
4. Ambrose LF, Freedman J, Buetow K, Friend S, Schilsky RL. Using patient-initiated study participation in the development of evidence for personalized cancer therapy. Clin Cancer Res 2011;17: 6651-7.
5. Rubin EH, Anderson KM, Gause CK. The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development. Cancer Discov 2011;1:17-20.
6. Simon R. The use of genomics in clinical trial design. Clin Cancer Res 2008;14:5984-93.
7. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive bio-marker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-34.
8. Printz C. BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery. Cancer 2010;116:3307-8.
9. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
10. Korn EL, Freidlin B. Outcomeadaptive randomization: is it useful? J Clin Oncol 2011;29:771-6.
11. United States Food and Drug Administration: 2010 draft guidance for industry on adaptive design clinical trials for drugs and biologics. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ ucm201790.pdf.
12. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005;11:7872-8. (Pubitemid 41611633)
13. Jiang W, Freidlin B, Simon R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 2007;99:1036-43. (Pubitemid 47232604)
14. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. Clin Cancer Res 2010;16:691-8.
15. Simon R. Clinical trials for predictive medicine: new challenges and paradigms. Clin Trials 2010;7:516-24.
16. Scher HI, Sawyers C. Biology of progressive castration resistant prostate cancer: directed therapies targeting the androgen receptor signaling axis. J Clin Oncol 2005;23:8253-61. (Pubitemid 46211563)
17. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27. (Pubitemid 38364606)
18. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
19. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-501.
20. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the cyp17 inhibitor abiraterone acetate. J Clin Oncol 2010;28:1489-95.
21. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
22. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
23. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.
24. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009;15:4792-8.
25. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
26. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
27. Nilsson S, O'Bryan-Tear CG, Bolstad B, Lokna A, Parker CC. Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223. [abstract]. In: Proceedings of the 2011 ASCO Annual Meeting; 2011 Jun 3-7; Chicago, IL: ASCO; 2011. Abstract nr 4620.
28. Positive outcome of interim analysis of pivotal Alpharadin study: primary endpoint met in phase III ALSYMPCA study [press release]. Oslo, Norway: Algeta ASA; 2011.
29. Wang SJ, O'Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 2007;6:227-44. (Pubitemid 47455262)
30. Dobbin KK, Simon RM. Sample size planning for developing classifiers using high-dimensional DNA microarray data. Biostatistics 2007;8:101-17. (Pubitemid 44906105)